Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 17:12:848036.
doi: 10.3389/fonc.2022.848036. eCollection 2022.

5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis

Luca Ricciardi  1 , Carmelo Lucio Sturiale  2   3 , Alba Scerrati  4   5 , Vito Stifano  2   3 , Teresa Somma  6 , Tamara Ius  7 , Sokol Trungu  1   8 , Michele Acqui  1 , Antonino Raco  1 , Massimo Miscusi  1 , Giuseppe Maria Della Pepa  2   3
Affiliations

5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis

Luca Ricciardi et al. Front Oncol. .

Abstract

Background: Several studies have confirmed the impact of 5-aminolevulinic acid (5-ALA) on the extent of resection in newly diagnosed glioblastoma (GBM). However, there are controversies on the 5-ALA fluorescence status in recurrent GBM surgery, with specific reference to pseudoprogression or radionecrosis; therefore, the safety and accuracy of surgical planning in 5-ALA-assisted procedures in the recurrent context are still unclear.

Materials and methods: This is a systematic review and meta-analysis of comparative studies on the use of 5-ALA in newly diagnosed and recurrent GBM, consistently conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Data on fluorescence status and correlation between fluorescence and histological findings were collected. We performed a meta-analysis of proportions to estimate the pooled rates of each outcome.

Results: Three online medical databases (PubMed, Scopus, Cochrane Library) were screened, 448 articles were evaluated, and 3 papers were finally included for data analysis. Fluorescence rate was not different between newly diagnosed and recurrent GBM [p = 0.45; odds ratio (OR): 1.23; 95% CI: 0.72-2.09; I2 = 0%], while the rate of 5-ALA fluorescence-positive areas not associated with histological findings of GBM cells was higher in recurrent GBM (p = 0.04; OR: 0.24; 95% CI: 0.06-0.91; I2 = 19%). Furthermore, there were no cases of radionecrosis in false-positive samples, while inflammation and signs of pseudoprogression were found in 81.4% of the cases.

Discussion and conclusions: Therefore, a robust awareness of 5-ALA potentialities and pitfalls in recurrent GBM surgery should be considered for a cognizant surgical strategy. Further clinical trials could confirm the results of the present meta-analysis.

Keywords: 5-ALA fluorescence; glioblastoma; high-grade glioma (HGG); pseudoprogression; radionecrosis; recurrent glioblastoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Search strategy.
Figure 2
Figure 2
5-Aminolevulinic acid (5-ALA) fluorescence rate in newly diagnosed and recurrent glioblastoma. The Foster Plot, from the meta-analyses of proportions to estimate the pooled rates of 5-ALA-positive fluorescence rate in newly diagnosed and recurrent glioblastoma. According to the Plot, there are no significative differences comparing the pooled rates from the two meta-analytic groups (p = 0.45).
Figure 3
Figure 3
5-Aminolevulinic acid (5-ALA) fluorescence-positive areas non-associated with histological finding of glioblastoma cells. The Foster Plot, from the meta-analyses of proportions to estimate the pooled rates of 5-ALA-positive fluorescence areas non-associated with histological finding of glioblastoma cells, defined in the paper as false-positive areas. According to the Plot, a significantly higher false-positive rate occurs in recurrent glioblastoma.
See this image and copyright information in PMC

References

    1. Schupper AJ, Yong RL, Hadjipanayis CG. The Neurosurgeon's Armamentarium for Gliomas: An Update on Intraoperative Technologies to Improve Extent of Resection. J Clin Med (2021) 10(2):236. doi: 10.3390/jcm10020236 - DOI - PMC - PubMed
    1. La Rocca G, Della Pepa GM, Menna G, Altieri R, Ius T, Rapisarda A, et al. . State of the Art of Fluorescence Guided Techniques in Neurosurgery. J Neurosurg Sci (2019) 63(6):619–24. doi: 10.23736/S0390-5616.19.04854-9 - DOI - PubMed
    1. Schipmann S, Muther M, Stogbauer L, Zimmer S, Brokinkel B, Holling M, et al. . Combination of ALA-Induced Fluorescence-Guided Resection and Intraoperative Open Photodynamic Therapy for Recurrent Glioblastoma: Case Series on a Promising Dual Strategy for Local Tumor Control. J Neurosurg (2020) 24:1–11. doi: 10.3171/2019.11.JNS192443 - DOI - PubMed
    1. Della Pepa GM, Ius T, La Rocca G, Gaudino S, Isola M, Pignotti F, et al. . 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery. Neurosurgery (2020) 86(6):E529–40. doi: 10.1093/neuros/nyaa037 - DOI - PubMed
    1. Navarro-Bonnet J, Suarez-Meade P, Brown DA, Chaichana KL, Quinones-Hinojosa A. Following the Light in Glioma Surgery: A Comparison of Sodium Fluorescein and 5-Aminolevulinic Acid as Surgical Adjuncts in Glioma Resection. J Neurosurg Sci (2019) 63(6):633–47. doi: 10.23736/S0390-5616.19.04745-3 - DOI - PubMed

Publication types

LinkOut - more resources